A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations.
We describe a simple quantitative bedside method for assessing the dopaminergic properties of new therapeutic agents, namely, by documenting their duration of action in patients with Parkinson's disease who exhibit "on-off" fluctuations. This model represents a form of human dopaminergic "bioassay".
Coleman
R J
RJ
Institute of Psychiatry, London, U.K.
Temlett
J A
JA
Quinn
N P
NP
Stahl
S M
SM
Marsden
C D
CD
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology*; D015259:Dopamine Agents / Q000494:pharmacology*; D004341:Drug Evaluation / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D010078:Oxazines; C042631:naxagolide